Joshua A Kazam insider trades
Open-market stock purchases and sales by Joshua A Kazam, Director at Allogene Therapeutics, Inc, from SEC Form 4 filings since Apr 22, 2010.
Track record: 50% of 2 scored buys are up 5% or more since purchase, averaging -8%.
Companies traded
- ALLO Allogene Therapeutics, Inc: 1 buy, last Jun 18, 2026
- KRON Kronos Bio, Inc: other filings, last Jun 20, 2025
- LTCH TS Innovation Acquisitions Corp: other filings, last Jun 4, 2021
- TSIB Tishman Speyer Innovation Corp II: 2 buys, last Feb 12, 2021
- DEAC Diamond Eagle Acquisition Corp \ DE: other filings, last Dec 31, 2019
- EAGL Platinum Eagle Acquisition Corp: other filings, last Jan 17, 2018
- CAPR Capricor Therapeutics, Inc: 1 buy, last Jan 2, 2018
- KITE Kite Pharma, Inc: other filings, last Oct 3, 2017
- NLTX Nile Therapeutics, Inc: 4 buys, last Mar 30, 2012